# A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies

> **NCT03130959** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 166 (actual)

## Conditions studied

- Various Advanced Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT03130959
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-12
- **Primary completion:** 2020-03-10
- **Final completion:** 2022-01-17
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2022-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03130959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03130959, "A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03130959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*